ERBB2 and breast cancer: Inetetamab may also be an option for neoadjuvant treatment of HER2-positive breast cancer patients, considering the combination of chemotherapeutic agents, the appropriate treatment duration, and the management of safety and adverse effects during the neoadjuvant phase.